Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
European Journal of Nuclear Medicine and Molecular Imaging|August 25, 2019
Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yieldF M Montes de Jesus, T C Kwee, X U Kahle, et al.
British Journal of Haematology|August 4, 2025
Clonal haematopoiesis associates with distinct cytometric changes of red blood cells and plateletsJ B Salzbrunn, I A van Zeventer, A O de Graaf, et al.
ESMO Open|January 31, 2025
The association between hospital volume and overall survival in adult AML patients treated with intensive chemotherapyZ L R Kaplan, N van Leeuwen, D van Klaveren, et al.
Leukemia|April 4, 2015
Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cellsL C J Te Boome, C Mansilla, L E van der Wagen, et al.
Leukemia|July 16, 2016
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratioJ Versluis, F E M In 't Hout, R Devillier, et al.
Leukemia|November 28, 2014
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 yearsJ J Cornelissen, J Versluis, J R Passweg, et al.
Leukemia|February 6, 2020
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDSG J Ossenkoppele, D A Breems, G Stuessi, et al.
Leukemia|August 1, 2020
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDSG J Ossenkoppele, D A Breems, G Stuessi, et al.
Leukemia|August 1, 2015
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyR Zeiser, A Burchert, C Lengerke, et al.
Pageof 4